{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:52:09Z","timestamp":1767833529589,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05182-5","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T17:03:28Z","timestamp":1660323808000},"page":"373-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Upfront rituximab therapy for thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a case-based review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5995-8609","authenticated-orcid":false,"given":"Tomoyuki","family":"Mutoh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"5182_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80:14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"key":"5182_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.498703","volume":"11","author":"K Akita","year":"2020","unstructured":"Akita K, Yasaka K, Shirai T, Ishii T, Harigae H, Fujii H (2020) Interferon alpha enhances B cell activation associated with FOXM1 induction: potential novel therapeutic strategy for targeting the plasmablasts of systemic lupus erythematosus. Front Immunol 11:498703. https:\/\/doi.org\/10.3389\/fimmu.2020.498703","journal-title":"Front Immunol"},{"key":"5182_CR3","doi-asserted-by":"publisher","unstructured":"American College of Rheumatology Ad Hoc Committee on systemic lupus erythematosus Guidelines (1999) Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 42, 1785\u20131796. https:\/\/doi.org\/10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2"},{"key":"5182_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0961203308094360","volume":"18","author":"SK Kwok","year":"2009","unstructured":"Kwok SK, Ju JH, Cho CS, Kim HY, Park SH (2009) Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus 18:16\u201321. https:\/\/doi.org\/10.1177\/0961203308094360","journal-title":"Lupus"},{"key":"5182_CR5","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier AT (2017) Thrombotic Thrombocytopenic purpura. Blood 129:2836\u20132846. https:\/\/doi.org\/10.1182\/blood-2016-10-709857","journal-title":"Blood"},{"key":"5182_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325:393\u2013397. https:\/\/doi.org\/10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"key":"5182_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0049-0172(98)80023-1","volume":"28","author":"F Musio","year":"1998","unstructured":"Musio F, Bohen EM, Yuan CM, Welch PG (1998) Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 28:1\u201319. https:\/\/doi.org\/10.1016\/s0049-0172(98)80023-1","journal-title":"Semin Arthritis Rheum"},{"key":"5182_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/ken510","volume":"48","author":"P Letchumanan","year":"2009","unstructured":"Letchumanan P, Ng HJ, Lee LH, Thumboo J (2009) A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford) 48:399\u2013403. https:\/\/doi.org\/10.1093\/rheumatology\/ken510","journal-title":"Rheumatology (Oxford)"},{"key":"5182_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keq395","volume":"50","author":"F Lansigan","year":"2011","unstructured":"Lansigan F, Isufi I, Tagoe CE (2011) Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13. Rheumatology (Oxford) 50:824\u2013829. https:\/\/doi.org\/10.1093\/rheumatology\/keq395","journal-title":"Rheumatology (Oxford)"},{"key":"5182_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood.2019000954","volume":"134","author":"MA Mazepa","year":"2019","unstructured":"Mazepa MA, Masias C, Chaturvedi S (2019) How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood 134:415\u2013420. https:\/\/doi.org\/10.1182\/blood.2019000954","journal-title":"Blood"},{"key":"5182_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"5182_CR12","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s10067-022-06155-6","volume":"41","author":"SJ Liang","year":"2022","unstructured":"Liang SJ, Zheng QY, Li MS, Lv MY, Chen WT, Yang Y (2022) Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review. Clin Rheumatol 41:2561\u20132569. https:\/\/doi.org\/10.1007\/s10067-022-06155-6","journal-title":"Clin Rheumatol"},{"key":"5182_CR13","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"key":"5182_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78:1151\u20131159. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214819","journal-title":"Ann Rheum Dis"},{"key":"5182_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312\u2013322. https:\/\/doi.org\/10.1111\/jth.13571","journal-title":"J Thromb Haemost"},{"key":"5182_CR16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","volume":"118","author":"M Scully","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118:1746\u20131753. https:\/\/doi.org\/10.1182\/blood-2011-03-341131","journal-title":"Blood"},{"key":"5182_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10067-013-2312-5","volume":"33","author":"H Jiang","year":"2014","unstructured":"Jiang H, An X, Li Y, Sun Y, Shen G, Tu Y, Tao J (2014) Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011. Clin Rheumatol 33:419\u2013427. https:\/\/doi.org\/10.1007\/s10067-013-2312-5","journal-title":"Clin Rheumatol"},{"key":"5182_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE et al (2018) Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93:789\u2013796. https:\/\/doi.org\/10.1016\/j.kint.2017.11.023","journal-title":"Kidney Int"},{"key":"5182_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"5182_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1006\/bcmd.2002.0522","volume":"28","author":"LA Gutterman","year":"2002","unstructured":"Gutterman LA, Kloster B, Tsai HM (2002) Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 28:385\u2013391. https:\/\/doi.org\/10.1006\/bcmd.2002.0522","journal-title":"Blood Cells Mol Dis"},{"key":"5182_CR21","first-page":"1194","volume":"33","author":"TB Niewold","year":"2006","unstructured":"Niewold TB, Alpert D, Scanzello CR, Paget SA (2006) Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol 33:1194\u20131196","journal-title":"J Rheumatol"},{"key":"5182_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ajh.20842","volume":"82","author":"M Feldman","year":"2007","unstructured":"Feldman M, Bruno T, Chong YC, Borstad G, Wild C, Lopez JD, George JN (2007) Bilateral nephrectomy for treatment resistant systemic lupus erythematosis and thrombotic thrombocytopenic purpura: a case report. Am J Hematol 82:496\u2013497. https:\/\/doi.org\/10.1002\/ajh.20842","journal-title":"Am J Hematol"},{"key":"5182_CR23","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s10067-007-0631-0","volume":"26","author":"T Kameda","year":"2007","unstructured":"Kameda T, Dobashi H, Kittaka K, Susaki K, Yamaoka G, Arai K, Tokuda M, Ishida T (2007) Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment. Clin Rheumatol 26:2159\u20132162. https:\/\/doi.org\/10.1007\/s10067-007-0631-0","journal-title":"Clin Rheumatol"},{"key":"5182_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncprheum0511","volume":"3","author":"AA Shah","year":"2007","unstructured":"Shah AA, Higgins JP, Chakravarty EF (2007) Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol 3:357\u2013362. https:\/\/doi.org\/10.1038\/ncprheum0511","journal-title":"Nat Clin Pract Rheumatol"},{"key":"5182_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1756-185X.2008.00334.x","volume":"11","author":"AG Halim","year":"2008","unstructured":"Halim AG, Soehardy Z, Shahrir MS, Rozita M, Loo CY, Rashidi S, Norella Kong CT (2008) Rituximab in recalcitrant thrombotic thrombocytopenic purpura secondary to systemic lupus erythematosus. Int J Rheum Dis 11:69\u201372. https:\/\/doi.org\/10.1111\/j.1756-185X.2008.00334.x","journal-title":"Int J Rheum Dis"},{"key":"5182_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0961203307083479","volume":"17","author":"N Limal","year":"2008","unstructured":"Limal N, Cacoub P, S\u00e8ne D, Guichard I, Piette JC (2008) Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus 17:69\u201371. https:\/\/doi.org\/10.1177\/0961203307083479","journal-title":"Lupus"},{"key":"5182_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10165-009-0231-8","volume":"20","author":"K Kamiya","year":"2010","unstructured":"Kamiya K, Kurasawa K, Arai S, Maezawa R, Hanaoka R, Kumano K, Fukuda T (2010) Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol 20:81\u201385. https:\/\/doi.org\/10.1007\/s10165-009-0231-8","journal-title":"Mod Rheumatol"},{"key":"5182_CR28","first-page":"109","volume":"21","author":"FA Niaz","year":"2010","unstructured":"Niaz FA, Aleem A (2010) Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transpl 21:109\u2013112","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"5182_CR29","first-page":"103","volume":"5","author":"SS El Khayat","year":"2012","unstructured":"El Khayat SS, Medkouri G, Etomba AM, Zamd M, Gharbi MB, Ramadani B (2012) Thrombotic thrombocytopenic purpura and systemic lupus erythematosus: a rare and life-threatening association. Arab J Nephrol Transplant 5:103\u2013105","journal-title":"Arab J Nephrol Transplant"},{"key":"5182_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/RHU.0b013e31825826ae","volume":"18","author":"TV Mai","year":"2012","unstructured":"Mai TV, Tse K, Gehr MK, George J, Baranski J, Xavier M (2012) Bilateral nephrectomy for the treatment of refractory lupus nephritis with features overlapping with thrombotic microangiopathy resembling thrombotic thrombocytopenia purpura. J Clin Rheumatol 18:185\u2013188. https:\/\/doi.org\/10.1097\/RHU.0b013e31825826ae","journal-title":"J Clin Rheumatol"},{"key":"5182_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.reuma.2012.11.005","volume":"9","author":"BR Garcia","year":"2013","unstructured":"Garcia BR, Mas Esteve E, Mas Esteve M, Mill\u00e1 Perseguer MM, Marco Buades J, Beltran Fabregat J, Ca\u00f1igral Ferrando G, Belmonte Serrano MA (2013) Systemic lupus erythematosus and thrombotic thrombocytopenia purpura: a refractory case without lupus activity. Reumatol Clin 9:373\u2013375. https:\/\/doi.org\/10.1016\/j.reuma.2012.11.005","journal-title":"Reumatol Clin"},{"key":"5182_CR32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.12659\/AJCR.898955","volume":"17","author":"M Abu-Hishmeh","year":"2016","unstructured":"Abu-Hishmeh M, Sattar A, Zarlasht F, Ramadan M, Abdel-Rahman A, Hinson S, Hwang C (2016) Systemic lupus erythematosus presenting as refractory thrombotic thrombocytopenic purpura: a diagnostic and management challenge. A case report and concise review of the literature. Am J Case Rep 17:782\u2013787. https:\/\/doi.org\/10.12659\/AJCR.898955","journal-title":"Am J Case Rep"},{"key":"5182_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s12026-017-8898-y","volume":"65","author":"NS Gonz\u00e1lez","year":"2017","unstructured":"Gonz\u00e1lez NS, Lorenzo N, Parodis Y, Ortiz MBA, Kechida M, Perez JCR (2017) Thrombotic thrombocytopenic purpura in a new onset lupus patient? Immunol Res 65:454\u2013458. https:\/\/doi.org\/10.1007\/s12026-017-8898-y","journal-title":"Immunol Res"},{"key":"5182_CR34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1177\/0961203320953473","volume":"29","author":"W Ma","year":"2020","unstructured":"Ma W, Bai W, Wu X, Zhao J, Li M, Zeng X (2020) Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. Lupus 29:1961\u20131967. https:\/\/doi.org\/10.1177\/0961203320953473","journal-title":"Lupus"},{"key":"5182_CR35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.thromres.2014.09.005","volume":"134","author":"J Merayo-Chalico","year":"2014","unstructured":"Merayo-Chalico J, Demichelis-G\u00f3mez R, Rajme-L\u00f3pez S, Aparicio-Vera L, Barrera-Vargas A, Alcocer-Varela J, G\u00f3mez-Mart\u00edn D (2014) Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum? A case control study. Thromb Res 134:1020\u20131027. https:\/\/doi.org\/10.1016\/j.thromres.2014.09.005","journal-title":"Thromb Res"},{"key":"5182_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","volume":"112","author":"M Kubo","year":"2020","unstructured":"Kubo M, Sakai K, Yoshii Y, Hayakawa M, Matsumoto M (2020) Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. Int J Hematol 112:764\u2013772. https:\/\/doi.org\/10.1007\/s12185-020-02974-y","journal-title":"Int J Hematol"},{"key":"5182_CR37","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","volume":"132","author":"M Jestin","year":"2018","unstructured":"Jestin M, Benhamou Y, Schelpe AS et al (2018) Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 132:2143\u20132153. https:\/\/doi.org\/10.1182\/blood-2018-04-840090","journal-title":"Blood"},{"key":"5182_CR38","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3899\/jrheum.170811","volume":"45","author":"C Yue","year":"2018","unstructured":"Yue C, Su J, Gao R, Wen Y, Li C, Chen G, Zhang X, Li X (2018) Characteristics and outcomes of patients with systemic lupus erythematosus-associated thrombotic microangiopathy, and their acquired ADAMTS13 inhibitor profiles. J Rheumatol 45:1549\u20131556. https:\/\/doi.org\/10.3899\/jrheum.170811","journal-title":"J Rheumatol"},{"key":"5182_CR39","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/trf.13182","volume":"55","author":"A Isonishi","year":"2015","unstructured":"Isonishi A, Bennett CL, Plaimauer B, Scheiflinger F, Matsumoto M, Fujimura Y (2015) Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion 55:2321\u20132330. https:\/\/doi.org\/10.1111\/trf.13182","journal-title":"Transfusion"},{"key":"5182_CR40","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ajh.24559","volume":"91","author":"Y Benhamou","year":"2016","unstructured":"Benhamou Y, Paintaud G, Azoulay E et al (2016) Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study. Am J Hematol 91:1246\u20131251. https:\/\/doi.org\/10.1002\/ajh.24559","journal-title":"Am J Hematol"},{"key":"5182_CR41","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","volume":"1","author":"JP Westwood","year":"2017","unstructured":"Westwood JP, Thomas M, Alwan F, McDonald V, Benjamin S, Lester WA, Lowe GC, Dutt T, Hill QA, Scully M (2017) Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv 1:1159\u20131166. https:\/\/doi.org\/10.1182\/bloodadvances.2017008268","journal-title":"Blood Adv"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05182-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05182-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05182-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T08:05:24Z","timestamp":1675411524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05182-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["5182"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05182-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}